Phathom Pharmaceuticals Inc (NASDAQ: PHAT) open the trading on Thursday, with great promise as it jumped 3.01% to $10.95, before settling in for the price of $10.63 at the close. Taking a more long-term approach, PHAT posted a 52-week range of $2.21-$19.71.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 12.50%. Meanwhile, its Annual Earning per share during the time was 12.50%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 38.26%. This publicly-traded company’s shares outstanding now amounts to $70.10 million, simultaneously with a float of $38.01 million. The organization now has a market capitalization sitting at $776.83 million. At the time of writing, stock’s 50-day Moving Average stood at $9.39, while the 200-day Moving Average is $7.31.
Phathom Pharmaceuticals Inc (PHAT) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Phathom Pharmaceuticals Inc’s current insider ownership accounts for 46.42%, in contrast to 46.11% institutional ownership. According to the most recent insider trade that took place on Jul 16 ’25, this organization’s Principal Accounting Officer sold 1,692 shares at the rate of 8.36, making the entire transaction reach 14,152 in total value, affecting insider ownership by 48,392. Preceding that transaction, on May 21 ’25, Company’s Director bought 3,780 for 3.86, making the whole transaction’s value amount to 14,609. This particular insider is now the holder of 59,403 in total.
Phathom Pharmaceuticals Inc (PHAT) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.28 per share during the current fiscal year.
Phathom Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 38.26% and is forecasted to reach -0.31 in the upcoming year.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Trading Performance Indicators
Let’s observe the current performance indicators for Phathom Pharmaceuticals Inc (PHAT). It’s Quick Ratio in the last reported quarter now stands at 2.35. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 6.81.
In the same vein, PHAT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -4.73, a figure that is expected to reach -0.47 in the next quarter, and analysts are predicting that it will be -0.31 at the market close of one year from today.
Technical Analysis of Phathom Pharmaceuticals Inc (PHAT)
[Phathom Pharmaceuticals Inc, PHAT] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 71.70% While, its Average True Range was 74.39%.
Raw Stochastic average of Phathom Pharmaceuticals Inc (PHAT) in the period of the previous 100 days is set at 86.45%, which indicates a major fall in contrast to 92.13% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.66 that was lower than 0.70 volatility it exhibited in the past 100-days period.
